Neisseria meningitidis capsular polysaccharide antigens conjugated to diphtheria toxoid (MenACWY-D)

Neisseria meningitidis capsular polysaccharide antigens conjugated to diphtheria toxoid is a vaccine formulation used to prevent invasive meningococcal disease caused by serogroups A, C, W-135, and Y (FDA, 2020). The bacterial capsule is the primary virulence factor of Neisseria meningitidis, enabling the pathogen to resist phagocytosis and complement-mediated killing (CDC, 2023). By covalently linking these polysaccharides to a diphtheria toxoid carrier protein, the vaccine transforms the immune response from T-cell independent to T-cell dependent (Pollard et al., 2009). This conjugation is essential for stimulating T-helper cells, which facilitate B-cell differentiation into memory cells and high-affinity antibody-producing plasma cells, ensuring efficacy in infants and young children (PubMed, 2011). The vaccine's effectiveness is primarily measured by the induction of serum bactericidal antibodies that mediate bacterial lysis in the presence of complement (StatPearls, 2023). While generally safe, the vaccine's effectiveness can be diminished in individuals receiving immunosuppressive therapies (NIH, 2022).

Other names

MenactraMeningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineQuadrivalent meningococcal conjugate vaccineMCV4

Induction of antigen-specific bactericidal antibodies that facilitate complement-mediated killing of Neisseria meningitidis serogroups A, C, W-135, and Y (FDA, 2020; StatPearls, 2023).